Compare IKT & AVNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | AVNW |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.9M | 264.7M |
| IPO Year | 2020 | 2007 |
| Metric | IKT | AVNW |
|---|---|---|
| Price | $1.65 | $19.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $5.55 | ★ $32.75 |
| AVG Volume (30 Days) | ★ 559.3K | 86.7K |
| Earning Date | 11-13-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.76 | ★ 90.00 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $243,858,000.00 |
| Revenue This Year | N/A | $5.50 |
| Revenue Next Year | $33.33 | $6.59 |
| P/E Ratio | ★ N/A | $99.79 |
| Revenue Growth | N/A | ★ 0.56 |
| 52 Week Low | $1.33 | $13.92 |
| 52 Week High | $2.61 | $27.02 |
| Indicator | IKT | AVNW |
|---|---|---|
| Relative Strength Index (RSI) | 25.79 | 45.53 |
| Support Level | $1.59 | $18.70 |
| Resistance Level | $1.74 | $19.65 |
| Average True Range (ATR) | 0.11 | 0.69 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 4.85 | 33.47 |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Aviat Networks Inc manufacture and sell a range of wireless transport and access networking products, solutions and services to two principal customer types. Communications Service Providers (CSPs): These include mobile and fixed telecommunications network operators, broadband and internet service providers and network operators which generate revenues from the communications services. Private network operators: These are customers which do not resell communications services but build networks for reasons of economics, autonomy, and/or security to support a wide variety of mission critical performance applications. Examples include federal, state and local government agencies, transportation agencies, energy and utility companies, public safety agencies and broadcast network operators.